Given the effect of Src signaling on ovarian cancer, Konecny et al (22) studied 34 ovarian cancer cell lines and demonstrated that dasatinib inhibits cell proliferation in vitro with 0.001–11.3 μM IC50 values. Here, SRC is linked to ovarian cancer.